CytomX Therapeutics (CTMX) Financials

CytomX Therapeutics logo
$1.96 -0.03 (-1.51%)
As of 11:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for CytomX Therapeutics

Annual Income Statements for CytomX Therapeutics

This table shows CytomX Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-42 -59 -43 -85 -133 -65 -116 -99 -0.57 32 -20
Consolidated Net Income / (Loss)
-35 -59 -43 -85 -133 -65 -116 -99 -0.57 32 -17
Net Income / (Loss) Continuing Operations
-35 -59 -43 -85 -133 -65 -116 -99 -0.57 32 -17
Total Pre-Tax Income
-35 -59 -44 -70 -133 -79 -116 -99 3.32 32 -17
Total Operating Income
-33 -60 -46 -78 -141 -81 -116 -101 -6.48 25 -22
Total Gross Profit
7.71 15 72 60 27 68 37 53 101 138 76
Total Revenue
7.71 15 72 60 27 68 37 53 101 138 76
Operating Revenue
7.71 15 72 60 27 68 37 53 101 138 76
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
41 75 118 137 168 149 153 154 108 113 99
Selling, General & Admin Expense
13 20 26 34 37 36 39 43 30 30 30
Research & Development Expense
28 55 92 104 132 113 114 112 78 83 69
Total Other Income / (Expense), net
-2.16 0.67 2.65 7.57 8.23 1.81 0.17 2.02 9.81 7.10 5.23
Interest & Investment Income
1.32 0.74 2.67 7.64 8.37 1.84 0.26 1.68 9.84 7.14 5.21
Other Income / (Expense), net
-1.74 -0.07 -0.03 -0.07 -0.14 -0.03 -0.08 0.34 -0.03 -0.04 0.03
Income Tax Expense
0.01 -0.02 -0.51 14 -0.43 -14 0.00 0.00 3.89 0.22 0.24
Basic Earnings per Share
($4.90) ($1.63) ($1.16) - ($2.93) ($1.40) ($1.81) ($1.51) ($0.01) $0.38 ($0.15)
Weighted Average Basic Shares Outstanding
8.60M 36.23M 37.17M 41.66M 45.34M 46.15M 64.15M 65.74M 73.81M 84.44M 137.94M
Diluted Earnings per Share
($4.90) ($1.63) ($1.16) - ($2.93) ($1.40) ($1.81) ($1.51) ($0.01) $0.38 ($0.15)
Weighted Average Diluted Shares Outstanding
8.60M 36.23M 37.17M 41.66M 45.34M 46.15M 64.15M 65.74M 73.81M 84.75M 137.94M
Weighted Average Basic & Diluted Shares Outstanding
8.60M 36.23M 37.17M 41.66M 45.34M 46.15M 65.39M 66.23M 67.72M 80.10M 170.19M

Quarterly Income Statements for CytomX Therapeutics

This table shows CytomX Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
14 -6.53 5.74 19 24 -0.15 -14 -30 -18 -21 -20
Consolidated Net Income / (Loss)
14 -6.53 5.74 19 24 -0.15 -14 -27 -18 -21 -20
Net Income / (Loss) Continuing Operations
14 -6.53 5.74 19 24 -0.15 -14 -27 -18 -21 -20
Total Pre-Tax Income
14 -6.48 5.80 19 24 -0.09 -14 -26 -18 -21 -20
Total Operating Income
12 -8.45 4.11 18 23 -1.29 -16 -28 -20 -24 -24
Total Gross Profit
41 25 33 38 51 19 5.96 0.66 10 1.42 1.69
Total Revenue
41 25 33 38 51 19 5.96 0.66 10 1.42 1.69
Operating Revenue
41 25 33 38 51 19 5.96 0.66 10 1.42 1.69
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
30 34 29 20 28 20 22 29 30 25 25
Selling, General & Admin Expense
7.75 8.40 7.95 5.62 9.43 6.62 6.43 7.36 11 7.60 8.71
Research & Development Expense
22 25 21 15 19 13 15 21 19 18 16
Total Other Income / (Expense), net
2.18 1.97 1.69 1.26 0.97 1.20 1.60 1.48 1.48 3.18 3.57
Interest & Investment Income
2.19 1.97 1.69 1.28 0.96 1.18 1.59 1.48 1.49 3.16 3.27
Other Income / (Expense), net
-0.01 -0.00 -0.01 -0.02 0.01 0.02 0.01 -0.01 -0.01 0.02 0.29
Income Tax Expense
0.05 0.05 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06
Basic Earnings per Share
$0.17 ($0.08) $0.07 $0.22 - - ($0.09) ($0.33) - - ($0.09)
Weighted Average Basic Shares Outstanding
82.03M 84.88M 85.09M 84.44M 87.12M 129.08M 165.00M 137.94M 177.27M 218.94M 219.11M
Diluted Earnings per Share
$0.17 ($0.08) $0.07 $0.22 - - ($0.09) ($0.33) - - ($0.09)
Weighted Average Diluted Shares Outstanding
82.63M 84.88M 85.20M 84.75M 87.15M 129.08M 165.00M 137.94M 177.27M 218.94M 219.11M
Weighted Average Basic & Diluted Shares Outstanding
- 78.12M 78.26M 80.10M 80.62M 164.91M 169.44M 170.19M 217.70M 217.90M 218.00M

Annual Cash Flow Statements for CytomX Therapeutics

This table details how cash moves in and out of CytomX Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-4.57 45 73 70 -59 3.43 14 -12 -176 21 -25
Net Cash From Operating Activities
-29 -2.03 170 -76 -140 5.26 -119 -111 -56 -86 -76
Net Cash From Continuing Operating Activities
-27 -2.03 170 -76 -140 5.26 -119 -111 -56 -86 -76
Net Income / (Loss) Continuing Operations
-35 -59 -43 -85 -133 -65 -116 -99 -0.57 32 -17
Consolidated Net Income / (Loss)
-35 -59 -43 -85 -133 -65 -116 -99 -0.57 32 -17
Depreciation Expense
-1.21 1.73 1.52 1.74 2.46 2.43 2.56 2.30 2.03 1.62 1.23
Amortization Expense
1.11 1.66 0.52 -1.56 -2.08 -0.09 0.42 0.09 -7.27 -5.17 -2.06
Non-Cash Adjustments To Reconcile Net Income
-0.79 14 212 17 23 18 16 17 12 12 11
Changes in Operating Assets and Liabilities, net
8.85 39 -0.46 -7.98 -31 50 -22 -31 -63 -126 -69
Net Cash From Investing Activities
-131 46 -121 5.93 80 -19 22 98 -151 100 -60
Net Cash From Continuing Investing Activities
-131 46 -121 5.93 80 -19 22 98 -151 100 -60
Purchase of Property, Plant & Equipment
-1.59 -2.18 -1.56 -3.79 -3.50 -2.31 -1.61 -1.74 -0.84 -0.31 -0.22
Purchase of Investments
-251 -122 -219 -205 -175 -199 -100 0.00 -425 -155 -193
Sale and/or Maturity of Investments
123 170 99 214 258 183 124 100 275 256 133
Net Cash From Financing Activities
153 1.00 24 140 1.63 17 110 0.65 30 7.52 110
Net Cash From Continuing Financing Activities
153 1.00 24 140 1.63 17 110 0.65 30 7.52 110
Issuance of Common Equity
82 0.93 24 140 1.63 17 110 0.65 30 7.52 110

Quarterly Cash Flow Statements for CytomX Therapeutics

This table details how cash moves in and out of CytomX Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
19 7.06 -2.56 -2.52 9.55 1.44 -15 -21 16 -12 17
Net Cash From Operating Activities
-26 -20 -21 -20 -21 -16 -16 -23 -26 -18 17
Net Cash From Continuing Operating Activities
-26 -20 -21 -20 -21 -16 -16 -23 -26 -18 17
Net Income / (Loss) Continuing Operations
14 -6.53 5.74 19 24 -0.15 -14 -27 -18 -21 -20
Consolidated Net Income / (Loss)
14 -6.53 5.74 19 24 -0.15 -14 -27 -18 -21 -20
Depreciation Expense
0.43 0.42 0.39 0.38 0.35 0.31 0.10 0.47 0.21 0.01 0.38
Amortization Expense
-1.83 -1.40 -1.18 -0.75 -0.42 -0.36 -0.60 -0.68 -0.69 -1.39 -1.33
Non-Cash Adjustments To Reconcile Net Income
2.89 2.89 3.03 3.05 3.09 2.54 2.52 3.04 5.84 3.94 3.91
Changes in Operating Assets and Liabilities, net
-41 -15 -29 -41 -48 -18 -3.33 0.43 -13 0.04 34
Net Cash From Investing Activities
45 22 18 15 31 -76 0.44 -14 -193 5.95 -0.00
Net Cash From Continuing Investing Activities
45 22 18 15 31 -76 0.44 -14 -193 5.95 -0.00
Purchase of Property, Plant & Equipment
-0.12 -0.10 -0.02 -0.08 -0.12 -0.03 0.13 -0.20 0.00 - -0.59
Purchase of Investments
0.00 -93 -12 -50 -20 -109 -20 -44 -243 -69 -65
Sale and/or Maturity of Investments
45 115 31 65 51 33 20 30 50 75 65
Net Cash From Financing Activities
0.17 5.10 - 2.25 0.00 94 0.25 17 234 0.51 0.09
Net Cash From Continuing Financing Activities
0.17 5.10 - 2.25 0.00 94 0.25 17 234 0.51 0.09
Issuance of Common Equity
0.17 5.10 - 2.25 0.00 94 0.25 17 234 0.51 0.09

Annual Balance Sheets for CytomX Therapeutics

This table presents CytomX Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
197 199 398 457 341 359 339 261 202 121 152
Total Current Assets
190 188 389 445 303 324 310 237 183 107 144
Cash & Equivalents
60 105 178 248 188 192 206 194 17 38 13
Restricted Cash
- - - - - - - - - - 0.00
Short-Term Investments
127 77 197 189 108 124 100 0.00 157 63 124
Accounts Receivable
0.74 2.31 10 0.10 0.01 0.80 0.79 36 3.43 3.10 2.01
Prepaid Expenses
2.30 3.90 4.35 9.25 7.18 7.10 4.29 7.47 5.00 3.58 4.86
Plant, Property, & Equipment, net
3.48 4.39 4.22 6.93 7.37 6.95 5.96 5.07 3.96 2.47 1.30
Total Noncurrent Assets
3.98 6.59 4.83 4.70 31 28 23 19 15 11 6.34
Goodwill
0.95 0.95 0.95 0.95 0.95 0.95 0.95 0.95 0.95 0.95 0.95
Intangible Assets
1.75 1.75 1.60 1.46 1.31 1.17 1.02 0.88 0.73 0.58 0.44
Other Noncurrent Operating Assets
0.36 3.89 2.27 2.29 28 26 21 17 13 9.23 4.95
Total Liabilities & Shareholders' Equity
197 199 398 457 341 359 339 261 202 121 152
Total Liabilities
71 121 328 326 290 366 340 347 249 121 53
Total Current Liabilities
16 36 61 98 86 68 78 153 156 86 47
Accounts Payable
4.70 6.60 4.21 5.13 4.16 3.00 2.82 2.81 1.46 1.09 1.30
Accrued Expenses
4.91 8.82 16 27 30 23 34 24 18 12 14
Current Deferred Revenue
6.13 20 41 53 51 42 41 121 132 67 27
Other Current Liabilities
- - - - - - - 4.08 4.59 5.15 4.24
Total Noncurrent Liabilities
55 85 267 228 205 298 262 194 93 35 5.94
Capital Lease Obligations
- - - - 25 22 18 14 9.39 4.24 0.00
Noncurrent Deferred Revenue
55 84 265 225 179 277 244 180 80 27 1.59
Other Noncurrent Operating Liabilities
0.20 0.57 1.90 3.05 0.85 - - 0.00 3.89 4.12 4.35
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
126 78 70 131 51 -7.77 -0.46 -86 -47 -0.46 99
Total Preferred & Common Equity
126 78 70 131 51 -7.77 -0.46 -86 -47 -0.46 99
Preferred Stock
- 0.00 - - 0.00 - - 0.00 0.00 0.00 0.00
Total Common Equity
126 78 70 131 51 -7.77 -0.46 -86 -47 -0.46 99
Common Stock
244 255 289 446 468 500 623 637 676 691 811
Retained Earnings
-117 -176 -219 -315 -417 -508 -624 -723 -723 -692 -712
Accumulated Other Comprehensive Income / (Loss)
-0.08 -0.03 -0.09 -0.09 0.06 -0.05 -0.24 0.01 0.10 0.03 0.11

Quarterly Balance Sheets for CytomX Therapeutics

This table presents CytomX Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
209 221 185 159 139 98 175 158 359 381 365
Total Current Assets
188 201 167 143 124 87 165 149 353 373 356
Cash & Equivalents
58 26 36 43 41 48 49 34 29 17 34
Restricted Cash
- - - - - - - - - 0.92 0.92
Short-Term Investments
123 168 114 94 77 32 109 109 318 313 314
Accounts Receivable
1.90 2.42 13 2.78 3.35 1.96 1.87 1.63 0.65 37 0.50
Prepaid Expenses
5.04 4.68 3.79 3.12 3.24 4.79 4.67 3.96 5.74 4.46 6.65
Plant, Property, & Equipment, net
4.50 4.06 3.57 3.32 2.94 2.23 1.95 1.72 1.09 1.08 2.52
Total Noncurrent Assets
17 16 14 13 12 9.64 8.49 7.32 5.17 6.99 6.11
Goodwill
0.95 0.95 0.95 0.95 0.95 0.95 0.95 0.95 0.95 0.95 0.95
Intangible Assets
0.80 0.77 0.69 0.66 0.62 0.55 0.51 0.47 0.40 0.37 0.33
Other Noncurrent Operating Assets
15 14 12 11 10 8.14 7.03 5.89 3.82 5.68 4.84
Total Liabilities & Shareholders' Equity
209 221 185 159 139 98 175 158 359 381 365
Total Liabilities
294 272 216 190 162 73 55 51 39 79 80
Total Current Liabilities
141 147 145 143 119 50 39 41 34 40 46
Accounts Payable
1.03 1.71 1.96 0.61 1.42 0.28 0.23 0.65 1.37 1.94 1.14
Accrued Expenses
20 21 14 14 17 11 12 12 12 12 16
Current Deferred Revenue
120 124 124 124 96 33 22 22 18 24 27
Other Current Liabilities
- - 4.72 4.86 5.00 5.29 5.44 5.60 2.86 1.50 0.53
Total Noncurrent Liabilities
153 126 72 48 43 23 16 9.84 5.39 39 34
Capital Lease Obligations
12 11 8.15 6.89 5.60 2.86 1.44 0.00 - 4.21 3.86
Noncurrent Deferred Revenue
141 112 60 37 34 16 10 5.54 0.98 31 26
Other Noncurrent Operating Liabilities
0.22 2.76 3.94 3.99 4.05 4.18 4.24 4.30 4.41 4.47 4.53
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-85 -51 -32 -31 -23 25 120 107 320 302 285
Total Preferred & Common Equity
-85 -51 -32 -31 -23 25 120 107 320 302 285
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-85 -51 -32 -31 -23 25 120 107 320 302 285
Common Stock
642 673 678 685 687 693 788 790 1,050 1,053 1,056
Retained Earnings
-727 -724 -710 -716 -710 -668 -668 -682 -730 -751 -771
Accumulated Other Comprehensive Income / (Loss)
0.04 -0.06 -0.01 -0.00 0.04 -0.00 0.03 0.10 0.10 -0.20 -0.32

Annual Metrics And Ratios for CytomX Therapeutics

This table displays calculated financial ratios and metrics derived from CytomX Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
36,024,292.00 36,402,346.00 38,408,626.00 45,007,104.00 45,434,164.00 46,224,402.00 65,249,116.00 66,084,367.00 66,988,904.00 78,258,879.00 170,186,742.00
DEI Adjusted Shares Outstanding
36,024,292.00 36,402,346.00 38,408,626.00 45,007,104.00 45,434,164.00 46,224,402.00 65,249,116.00 66,084,367.00 66,988,904.00 78,258,879.00 170,186,742.00
DEI Earnings Per Adjusted Shares Outstanding
-1.17 -1.62 -1.12 -1.88 -2.92 -1.40 -1.78 -1.50 -0.01 0.41 -0.12
Growth Metrics
- - - - - - - - - - -
Profitability Metrics
- - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)
-23 -42 -32 -55 -99 -56 -81 -71 1.11 25 -16
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -2.92% 655.93% -15.81%
Earnings before Interest and Taxes (EBIT)
-35 -60 -46 -78 -142 -81 -116 -101 -6.51 25 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-35 -56 -44 -78 -141 -78 -113 -99 -12 21 -23
Valuation Ratios
- - - - - - - - - - -
Leverage & Solvency
- - - - - - - - - - -
Liquidity Ratios
- - - - - - - - - - -
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-25 0.19 168 -53 -184 26 -96 -93 -52 -91 -74
Efficiency Ratios
- - - - - - - - - - -
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-62 -103 -304 -305 -220 -302 -288 -265 -213 -97 -38
Increase / (Decrease) in Invested Capital
1.78 -42 -201 -1.03 85 -82 15 22 53 116 59
Book Value per Share
$3.50 $2.16 $1.82 $2.91 $1.13 ($0.17) ($0.01) ($1.30) ($0.71) ($0.01) $0.58
Tangible Book Value per Share
$3.42 $2.08 $1.75 $2.85 $1.08 ($0.21) ($0.04) ($1.33) ($0.73) ($0.03) $0.58
Total Capital
126 78 70 131 76 14 18 -72 -38 3.78 99
Total Debt
0.00 0.00 0.00 0.00 25 22 18 14 9.39 4.24 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 25 22 18 14 9.39 4.24 0.00
Net Debt
-187 -182 -374 -436 -271 -294 -287 -180 -165 -96 -137
Capital Expenditures (CapEx)
1.59 2.12 1.56 3.79 3.50 2.31 1.61 1.74 0.84 0.31 0.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-13 -30 -47 -89 -78 -60 -73 -109 -147 -79 -40
Debt-free Net Working Capital (DFNWC)
174 152 327 348 218 256 232 84 27 22 97
Net Working Capital (NWC)
174 152 327 348 218 256 232 84 27 22 97
Net Nonoperating Expense (NNE)
12 17 11 30 34 8.44 35 28 1.68 -7.05 1.71
Net Nonoperating Obligations (NNO)
-188 -182 -374 -436 -271 -294 -287 -180 -165 -96 -137
Total Depreciation and Amortization (D&A)
-0.10 3.40 2.03 0.18 0.38 2.34 2.98 2.39 -5.24 -3.54 -0.83
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 ($1.16) ($2.03) ($2.26) $0.00 ($1.30) $0.00 ($0.01) $0.38 ($0.15)
Adjusted Weighted Average Basic Shares Outstanding
36.08M 36.52M 38.61M 45.11M 45.57M 64.78M 65.39M 0.00 73.81M 84.44M 137.94M
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($1.16) ($2.03) ($2.26) $0.00 ($1.30) $0.00 ($0.01) $0.38 ($0.15)
Adjusted Weighted Average Diluted Shares Outstanding
36.08M 36.52M 38.61M 45.11M 45.57M 64.78M 65.39M 0.00 73.81M 84.75M 137.94M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 ($1.16) ($2.03) ($2.26) $0.00 ($1.30) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
8.60M 36.23M 37.17M 41.66M 45.34M 46.15M 64.15M 0.00 67.72M 80.10M 170.19M
Normalized Net Operating Profit after Tax (NOPAT)
-23 -42 -32 -55 -99 -56 -81 -71 -4.54 25 -16
Debt Service Ratios
- - - - - - - - - - -
Payout Ratios
- - - - - - - - - - -

Quarterly Metrics And Ratios for CytomX Therapeutics

This table displays calculated financial ratios and metrics derived from CytomX Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
67,721,658.00 67,721,658.00 78,117,601.00 78,258,879.00 80,099,889.00 80,621,293.00 164,912,906.00 170,186,742.00 170,186,742.00 217,702,919.00 217,899,284.00
DEI Adjusted Shares Outstanding
67,721,658.00 67,721,658.00 78,117,601.00 78,258,879.00 80,099,889.00 80,621,293.00 164,912,906.00 170,186,742.00 170,186,742.00 217,702,919.00 217,899,284.00
DEI Earnings Per Adjusted Shares Outstanding
0.20 -0.10 0.07 0.24 0.29 0.00 -0.09 -0.17 -0.11 -0.09 -0.09
Growth Metrics
- - - - - - - - - - -
Revenue Growth
76.45% 1.58% 26.71% 43.17% 22.80% -25.71% -82.16% - -79.85% -92.40% -71.69%
EBITDA Growth
255.78% -109.16% 98.74% 839.71% 120.19% 86.02% -590.94% - -189.32% -1,806.29% -48.53%
EBIT Growth
306.56% -149.01% 31.71% 3,058.29% 94.33% 84.99% -484.09% - -186.95% -1,772.58% -47.23%
NOPAT Growth
393.54% -152.45% 153.15% 6,721.18% 94.23% 84.78% -371.34% - -161.03% -1,749.22% -49.05%
Net Income Growth
516.52% -501.10% 91.71% 2,155.20% 70.58% 97.64% -348.06% - -177.57% -13,319.48% -40.54%
EPS Growth
440.00% -300.00% 75.00% 1,000.00% 58.82% 100.00% -228.57% - 0.00% 0.00% 0.00%
Operating Cash Flow Growth
-378.59% 22.36% -13.63% 9.36% 19.21% 19.42% 24.99% - -21.41% -14.70% 207.07%
Free Cash Flow Firm Growth
-195.66% -211.44% -211.26% -84.69% -6.94% -27.56% -15.76% - 60.73% 77.36% 106.77%
Invested Capital Growth
37.54% 36.44% 42.30% 54.44% 70.09% 77.26% 73.25% - 48.51% 32.16% -65.98%
Revenue Q/Q Growth
55.83% -39.43% 33.12% 13.94% 33.67% -63.36% -68.04% - 1,447.21% -86.18% 19.04%
EBITDA Q/Q Growth
538.47% -192.06% 135.12% 421.79% 30.52% -105.85% -1,133.13% - 28.39% -24.76% 3.92%
EBIT Q/Q Growth
2,050.75% -172.59% 148.55% 330.34% 28.15% -105.61% -1,142.16% - 29.56% -20.75% 2.34%
NOPAT Q/Q Growth
4,464.87% -150.93% 168.75% 333.17% 28.04% -103.99% -1,126.13% - 29.57% -20.89% 1.17%
Net Income Q/Q Growth
1,547.67% -147.38% 187.79% 229.08% 24.63% -100.65% -9,139.61% - 31.17% -13.25% 3.23%
EPS Q/Q Growth
750.00% -147.06% 187.50% 214.29% 22.73% -100.00% 0.00% - 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
-18.59% 24.94% -6.04% 3.96% -5.70% 25.14% 1.30% - -9.92% 29.28% 192.14%
Free Cash Flow Firm Q/Q Growth
-74.76% -6.14% 3.34% -3.02% -1.18% -26.61% 12.29% - 50.24% 27.00% 126.21%
Invested Capital Q/Q Growth
18.23% 7.07% 16.15% 28.50% 46.32% 29.33% 1.36% - 29.65% 6.88% -141.35%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
EBITDA Margin
24.71% -37.56% 9.91% 45.38% 44.31% -7.07% -272.77% - -196.47% -1,773.20% -1,431.16%
Operating Margin
28.11% -33.65% 12.30% 46.41% 44.43% -6.89% -264.43% - -191.77% -1,677.08% -1,392.30%
EBIT Margin
28.09% -33.66% 12.28% 46.36% 44.45% -6.80% -264.35% - -191.84% -1,675.81% -1,374.88%
Profit (Net Income) Margin
33.26% -26.02% 17.16% 49.55% 46.20% -0.83% -238.62% - -177.89% -1,457.40% -1,184.72%
Tax Burden Percent
99.65% 100.79% 98.95% 99.67% 99.74% 169.23% 100.41% - 100.32% 100.29% 100.31%
Interest Burden Percent
118.84% 76.69% 141.25% 107.24% 104.22% 7.17% 89.90% - 92.43% 86.71% 85.91%
Effective Tax Rate
0.35% 0.00% 1.05% 0.33% 0.26% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Equity (ROE)
-27.95% -19.07% -37.03% -133.06% -1,254.80% 108.21% 66.76% - -34.29% -37.75% -43.55%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
15.97% -21.85% 8.63% 39.73% 46.32% -5.74% -202.12% - -29.78% -110.27% -73.76%
Return on Assets (ROA)
18.91% -16.89% 12.06% 42.46% 48.15% -0.70% -182.45% - -27.62% -95.90% -63.56%
Return on Common Equity (ROCE)
-27.95% -19.07% -37.03% -133.06% -1,254.80% 108.21% 66.76% - -34.29% -37.75% -43.55%
Return on Equity Simple (ROE_SIMPLE)
-52.19% 0.00% 0.00% 0.00% 166.09% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
12 -5.92 4.07 18 23 -0.90 -11 -20 -14 -17 -16
NOPAT Margin
28.01% -23.56% 12.17% 46.26% 44.31% -4.82% -185.10% - -134.24% -1,173.96% -974.61%
Net Nonoperating Expense Percent (NNEP)
1.30% -0.41% 1.13% 0.96% 0.88% 0.52% -2.50% - -2.11% -1.66% -1.45%
Return On Investment Capital (ROIC_SIMPLE)
-49.36% 24.31% -22.78% 465.65% 80.85% -0.74% -10.28% -19.75% -4.30% -5.44% -5.70%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
18.70% 33.43% 23.79% 14.76% 18.52% 35.49% 107.78% - 104.23% 536.04% 516.00%
R&D to Revenue
53.18% 100.23% 63.91% 38.83% 37.06% 71.40% 256.65% - 187.54% 1,241.04% 976.30%
Operating Expenses to Revenue
71.89% 133.65% 87.70% 53.59% 55.57% 106.89% 364.43% - 291.77% 1,777.08% 1,492.30%
Earnings before Interest and Taxes (EBIT)
12 -8.45 4.10 18 23 -1.27 -16 -28 -20 -24 -23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
10 -9.43 3.31 17 23 -1.32 -16 -28 -20 -25 -24
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 2.03 1.53 4.90 - 2.50 2.70 2.08
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 2.16 1.55 4.96 - 2.51 2.71 2.09
Price to Revenue (P/Rev)
1.24 0.69 0.73 0.58 0.35 1.30 4.63 - 22.51 44.61 42.25
Price to Earnings (P/E)
8.93 7.45 6.67 2.53 1.22 3.81 18.78 - 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Yield
11.20% 13.42% 15.00% 39.54% 81.69% 26.22% 5.33% - 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.05 0.00 0.00 0.00 0.00 0.19 3.37 - 12.75 26.74 17.66
Enterprise Value to EBITDA (EV/EBITDA)
1.08 0.00 0.00 0.00 0.00 0.63 17.18 - 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.51 0.00 0.00 0.00 0.00 0.61 16.44 - 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.63 0.00 0.00 0.00 0.00 0.61 16.60 - 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
-0.26 -0.22 -0.24 -9.30 0.11 0.01 0.00 - 0.00 0.01 0.01
Long-Term Debt to Equity
-0.26 -0.22 -0.24 -9.30 0.11 0.01 0.00 - 0.00 0.01 0.01
Financial Leverage
2.82 2.58 3.96 5.46 33.05 -3.24 -3.05 - -1.23 -1.15 -1.25
Leverage Ratio
-3.54 -3.17 -4.82 -6.73 -42.71 3.77 3.54 - 1.33 1.32 1.33
Compound Leverage Factor
-4.21 -2.43 -6.81 -7.22 -44.51 0.27 3.18 - 1.23 1.14 1.15
Debt to Total Capital
-34.63% -28.28% -31.34% 112.05% 10.23% 1.19% 0.00% - 0.00% 1.37% 1.34%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
-34.63% -28.28% -31.34% 112.05% 10.23% 1.19% 0.00% - 0.00% 1.37% 1.34%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Common Equity to Total Capital
134.63% 128.28% 131.34% -12.05% 89.77% 98.81% 100.00% - 100.00% 98.63% 98.66%
Debt to EBITDA
1.61 47.81 3.13 0.20 0.08 0.03 0.00 - 0.00 -0.05 -0.04
Net Debt to EBITDA
-28.05 -904.84 -62.57 -4.50 -2.28 -3.74 0.00 - 0.00 3.65 3.54
Long-Term Debt to EBITDA
1.61 47.81 3.13 0.20 0.08 0.03 0.00 - 0.00 -0.05 -0.04
Debt to NOPAT
0.93 1.64 0.91 0.17 0.08 0.03 0.00 - 0.00 -0.07 -0.06
Net Debt to NOPAT
-16.26 -30.97 -18.17 -3.88 -2.15 -3.65 0.00 - 0.00 5.36 5.19
Long-Term Debt to NOPAT
0.93 1.64 0.91 0.17 0.08 0.03 0.00 - 0.00 -0.07 -0.06
Altman Z-Score
-3.97 -5.46 -5.76 -5.79 -6.38 -1.71 1.38 - 10.32 4.32 2.35
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.16 1.00 1.04 1.25 1.73 4.20 3.64 - 10.38 9.36 7.82
Quick Ratio
1.13 0.98 1.01 1.21 1.63 4.08 3.54 - 10.21 9.23 7.65
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-93 -99 -95 -98 -99 -126 -110 -78 -39 -28 7.46
Operating Cash Flow to CapEx
-22,647.83% -20,363.54% -109,100.00% -24,885.00% -17,683.19% -58,344.44% 0.00% - 0.00% 0.00% 2,826.49%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.57 0.65 0.70 0.86 1.04 0.84 0.76 - 0.16 0.07 0.05
Accounts Receivable Turnover
16.71 51.12 43.88 42.27 19.50 60.77 45.63 - 27.32 0.93 13.17
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Fixed Asset Turnover
29.28 30.60 36.17 42.99 50.92 53.63 48.74 - 21.42 12.10 6.62
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Sales Outstanding (DSO)
21.85 7.14 8.32 8.64 18.72 6.01 8.00 - 13.36 392.51 27.71
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
21.85 7.14 8.32 8.64 18.72 6.01 8.00 - 13.36 392.51 27.71
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-174 -162 -135 -97 -52 -37 -36 -38 -27 -25 -60
Invested Capital Turnover
-0.53 -0.58 -0.68 -0.89 -1.31 -1.42 -1.32 - -0.90 -0.59 -0.29
Increase / (Decrease) in Invested Capital
104 93 99 116 122 125 99 59 25 12 -24
Enterprise Value (EV)
5.50 -48 -20 -16 -26 26 382 - 453 489 248
Market Capitalization
148 83 92 81 51 183 526 - 800 816 593
Book Value per Share
($0.47) ($0.37) ($0.30) ($0.01) $0.31 $1.49 $0.65 $0.58 $1.88 $1.39 $1.31
Tangible Book Value per Share
($0.49) ($0.39) ($0.32) ($0.03) $0.29 $1.47 $0.64 $0.58 $1.87 $1.38 $1.30
Total Capital
-24 -24 -18 3.78 28 121 107 99 320 306 289
Total Debt
8.15 6.89 5.60 4.24 2.86 1.44 0.00 0.00 0.00 4.21 3.86
Total Long-Term Debt
8.15 6.89 5.60 4.24 2.86 1.44 0.00 0.00 0.00 4.21 3.86
Net Debt
-142 -130 -112 -96 -77 -157 -144 -137 -347 -327 -345
Capital Expenditures (CapEx)
0.12 0.10 0.02 0.08 0.12 0.03 -0.13 0.20 0.00 0.00 0.59
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-128 -137 -113 -79 -43 -33 -35 -40 -28 2.10 -38
Debt-free Net Working Capital (DFNWC)
23 0.22 4.95 22 36 125 108 97 319 333 311
Net Working Capital (NWC)
23 0.22 4.95 22 36 125 108 97 319 333 311
Net Nonoperating Expense (NNE)
-2.18 0.62 -1.67 -1.26 -0.96 -0.75 3.19 6.96 4.48 4.02 3.55
Net Nonoperating Obligations (NNO)
-142 -130 -112 -96 -77 -157 -144 -137 -347 -327 -345
Total Depreciation and Amortization (D&A)
-1.40 -0.98 -0.79 -0.37 -0.07 -0.05 -0.50 -0.21 -0.48 -1.38 -0.95
Debt-free, Cash-free Net Working Capital to Revenue
-107.04% -114.54% -88.96% -57.27% -29.45% -23.17% -31.19% - -77.75% 11.46% -273.62%
Debt-free Net Working Capital to Revenue
19.06% 0.19% 3.91% 15.59% 24.69% 88.87% 95.21% - 897.74% 1,821.08% 2,213.70%
Net Working Capital to Revenue
19.06% 0.19% 3.91% 15.59% 24.69% 88.87% 95.21% - 897.74% 1,821.08% 2,213.70%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.17 ($0.08) $0.07 $0.22 $0.27 $0.00 ($0.09) ($0.33) $0.00 $0.00 ($0.09)
Adjusted Weighted Average Basic Shares Outstanding
82.03M 84.88M 85.09M 84.44M 87.12M 129.08M 165.00M 137.94M 177.27M 218.94M 219.11M
Adjusted Diluted Earnings per Share
$0.17 ($0.08) $0.07 $0.22 $0.27 $0.00 ($0.09) ($0.33) $0.00 $0.00 ($0.09)
Adjusted Weighted Average Diluted Shares Outstanding
82.63M 84.88M 85.20M 84.75M 87.15M 129.08M 165.00M 137.94M 177.27M 218.94M 219.11M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 78.12M 78.26M 80.10M 80.62M 164.91M 169.44M 170.19M 217.70M 217.90M 218.00M
Normalized Net Operating Profit after Tax (NOPAT)
12 -5.92 4.07 18 23 -0.90 -11 -20 -14 -17 -16
Normalized NOPAT Margin
28.01% -23.56% 12.17% 46.26% 44.31% -4.82% -185.10% - -134.24% -1,173.96% -974.61%
Pre Tax Income Margin
33.38% -25.81% 17.34% 49.72% 46.32% -0.49% -237.65% - -177.32% -1,453.17% -1,181.10%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

CytomX Therapeutics’ financial profile has changed substantially over the past several years. Total assets increased from $98.5 million in Q1 2024 to $381.2 million in Q2 2026, largely reflecting equity financing and accumulated cash investments. At June 30, 2026, the company held approximately $330.1 million in cash, restricted cash and short-term investments, compared with total liabilities of $79.2 million.

However, the company remains unprofitable and dependent on funding and collaboration-related revenue. Q2 2026 revenue fell to $1.4 million from $10.3 million in Q1 and $18.7 million in Q2 2025. CytomX reported a $20.7 million net loss and used $18.1 million in operating cash during the quarter. The operating cash burn improved from $25.5 million in Q1 2026, but cash flow has remained negative in nearly every quarter provided.

The latest statements show strong liquidity but continued execution and dilution risk. Research and development spending remains the largest expense, while revenue has been highly volatile. Investors should also note that the Q1 2025 and Q2 2025 income statements were restated, making comparisons with earlier periods less certain.

  • Strong liquidity position: Cash, restricted cash and short-term investments totaled approximately $330.1 million at the end of Q2 2026, providing a substantial funding cushion for ongoing research and development.
  • Improved balance-sheet strength: Total equity rose to $302.1 million in Q2 2026 from negative equity of $31.7 million in Q1 2024, while total liabilities declined from $216.4 million to $79.2 million over the same period.
  • Lower quarterly operating burn: Net cash used in operating activities improved to $18.1 million in Q2 2026 from $25.5 million in Q1 2026 and $23.2 million in Q4 2025.
  • Reduced deferred-revenue obligations: Current and noncurrent deferred revenue declined to approximately $54.5 million in Q2 2026 from more than $183 million in Q1 2024, reducing the amount of revenue-related obligations on the balance sheet.
  • Investment income supports results: Interest and investment income increased to $3.2 million in Q2 2026 from $1.5 million in Q1 2026, partially offsetting operating losses.
  • Revenue remains lumpy: Quarterly revenue has ranged from $663,000 in Q4 2025 to $50.9 million in Q1 2025. This pattern suggests that collaboration or milestone revenue may not be consistent from quarter to quarter.
  • Large investment portfolio: Short-term investments represented $313.1 million of the company’s current assets at June 30, 2026. These assets provide liquidity, but investment balances can fluctuate and are not the same as recurring operating revenue.
  • Persistent operating losses: CytomX reported net losses of $18.2 million in Q1 2026 and $20.7 million in Q2 2026, following a $26.5 million loss in Q4 2025.
  • Continued negative operating cash flow: Operating cash flow has been negative across the recent quarters provided, including $21.0 million used in Q1 2025, $15.5 million in Q2 2025, $23.2 million in Q4 2025, and $43.6 million during the first half of 2026.
  • Significant shareholder dilution: The weighted-average share count increased from approximately 82 million in Q1 2024 to approximately 219 million in Q2 2026. The company raised $234.5 million through common equity issuance in Q1 2026, which strengthened liquidity but diluted existing shareholders.
11/17/26 11:44 AM ETAI Generated. May Contain Errors.

CytomX Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, CytomX Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

CytomX Therapeutics' net income appears to be on an upward trend, with a most recent value of -$17.37 million in 2025, rising from -$35.37 million in 2015. The previous period was $31.87 million in 2024. View CytomX Therapeutics' forecast to see where analysts expect CytomX Therapeutics to go next.

CytomX Therapeutics' total operating income in 2025 was -$22.36 million, based on the following breakdown:
  • Total Gross Profit: $76.20 million
  • Total Operating Expenses: $98.57 million

Over the last 10 years, CytomX Therapeutics' total revenue changed from $7.71 million in 2015 to $76.20 million in 2025, a change of 888.1%.

In the past 13 quarters, CytomX Therapeutics' cash and equivalents has ranged from $17.22 million in Q2 2026 to $57.54 million in Q2 2023, and is currently $33.96 million as of their latest financial filing in Q3 2026.

CytomX Therapeutics had total debt of $0.00 at the end of 2025, a 100.0% decrease from 2024, and none in 2015.

Over the last 10 years, CytomX Therapeutics' book value per share changed from 3.50 in 2015 to 0.58 in 2025, a change of -83.3%.



Financial statements for NASDAQ:CTMX last updated on 11/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners